Cancer/testis antigens: Novel tools for discerning aggressive and non-aggressive prostate cancer

Asian Journal of Andrology

Volumn 14, Issue 3, 2012, Pages 400-404

  Shiraishi, Takumi ^a,b   Getzenberg, Robert H ^a,c   Kulkarni, Prakash ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer testis antigens; DNA microarrays; prostate cancer; prostate carcinoma tumor antigen

Indexed keywords

ACTB ANTIGEN; CANCER TESTIS ANTIGEN; CEP55 ANTIGEN; CSAG2 ANTIGEN; MAGEA12 ANTIGEN; MAGEA2 ANTIGEN; NUF2 ANTIGEN; PAGE4 ANTIGEN; PBK ANTIGEN; PROSTATE SPECIFIC ANTIGEN; SSX2 ANTIGEN; TBP ANTIGEN; TTK ANTIGEN; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CANCER PROGNOSIS; HUMAN; MALE; PROSTATE CANCER; REVIEW;

ANTIGENS, NEOPLASM; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; TESTIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860864515     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.144     Document Type: Review

References (45)

1. Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: Perspectives from autopsy studies. Can J Urol 2008; 15: 3866-3871.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
3. Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000; 88: 2398-2424. (Pubitemid 30247142)
4. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E et al. Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J Natl Cancer Inst 2009; 101: 374-383.
5. Stephenson RA, Stanford JL. Population-based prostate cancer trends in the United States: Patterns of change in the era of prostate-specific antigen. World J Urol 1997; 15: 331-335. (Pubitemid 127764016)
6. Galper SL, Chen MH, Catalona WJ, Roehl KA, Richie JP et al. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 2006; 175: 907-912. (Pubitemid 43200015)
7. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery-what we have learned and where we are going. J Urol 1999; 162: 293-306. (Pubitemid 29434327)
8. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597. (Pubitemid 29211767)
9. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997; 24: 395-406. (Pubitemid 27169264)
10. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 1837-1842. (Pubitemid 24322641)
11. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-Term results. J Urol 1998; 160: 2428-2434.
12. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152: 1843-1849. (Pubitemid 24322642)
13. Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994; 152: 1821-1825. (Pubitemid 24322638)
14. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP et al. Long-Term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850-1857. (Pubitemid 24322643)
15. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-Term biochemical diseasefree and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28: 555-565. (Pubitemid 32916759)
16. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 517-523. (Pubitemid 36132976)
17. Kattan MW, Eastham J. Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer. Clin Prostate Cancer 2003; 1: 221-226. (Pubitemid 37021458)
18. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23: 7005-7012.
19. Kattan MW, Vickers AJ, Yu C, Bianco FJ, Cronin AM et al. Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer 2009; 115: 1005-1010.
20. Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. Cancer 2008; 113: 3075-3099.
21. Agrawal S, Dunsmuir WD. Molecular markers in prostate cancer. Part I: Predicting lethality. Asian J Androl 2009; 11: 14-21.
22. Makarov DV, Loeb S, Getzenberg RH, Partin AW. Biomarkers for prostate cancer. Annu Rev Med 2009; 60: 139-151.
23. Netto GJ. Molecular diagnostics in urologic malignancies: A work in progress. Arch Pathol Lab Med 2011; 135: 610-621.
24. Lopergolo A, Zaffaroni N. Biomolecular markers of outcome prediction in prostate cancer. Cancer 2009; 115: 3058-3067.
25. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: Review, standardization, and commentary. Cancer Immun 2004; 4: 1.
26. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-625. (Pubitemid 41081387)
27. Brichard VG, Lejeune D. GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development. Vaccine 2007; 25 Suppl 2: B61-71. (Pubitemid 47488551)
28. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA et al. Cancer-Testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11: 8055-8062. (Pubitemid 41698748)
29. Velazquez EF, Jungbluth AA, Yancovitz M, Gnjatic S, Adams S et al. Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)-correlation with prognostic factors. Cancer Immun 2007; 7: 11.
30. Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F et al. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 2008; 8: 2.
31. Napoletano C, Bellati F, Tarquini E, Tomao F, Taurino F et al. MAGE-A and NY-ESO-1 expression in cervical cancer: Prognostic factors and effects of chemotherapy. Am J Obstet Gynecol 2008; 198: 99.e1-7.
32. Grigoriadis A, Caballero OL, Hoek KS, da Silva L, Chen YT et al. CT-X antigen expression in human breast cancer. Proc Natl Acad Sci USA 2009; 106: 13493-8.
33. Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, Mundstein AS et al. CTdatabase: A knowledge-base of high-Throughput and curated data on cancer-Testis antigens. Nucleic Acids Res 2009; 37: D816-9.
34. Nakada T, Noguchi Y, Satoh S, Ono T, Saika T et al. NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. Cancer Immun 2003; 3: 10.
35. Fossa A, Berner A, Fossa SD, Hernes E, Gaudernack G et al. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 2004; 59: 440-447. (Pubitemid 38661812)
36. Hudolin T, Juretic A, Spagnoli GC, Pasini J, Bandic D et al. Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue. Prostate 2006; 66: 13-18. (Pubitemid 43005945)
37. Smith HA, Cronk RJ, Lang JM, McNeel DG. Expression and immunotherapeutic targeting of the SSX family of cancer-Testis antigens in prostate cancer. Cancer Res 2011; 71: 6785-6795.
38. Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N et al. Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate 2010; 70: 1778-1787.
39. Shiraishi T, Terada N, Zeng Y, Suyama T, Luo J et al. Cancer/testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med 2011; 9: 153.
40. Khan MA, Partin AW, Mangold LA, Epstein JI, Walsh PC. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology 2003; 62: 866-871. (Pubitemid 37421233)
41. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002; 167: 528-534. (Pubitemid 34074521)
42. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-Term results. J Urol 2004; 172: 910-914. (Pubitemid 39096421)
43. von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G et al. MAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancer. PLoS ONE 2011; 6: E21366.
44. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol 2011; 29: 2391-2396.
45. Cuzick J, Swanson GP, Fisher G, Brothman AR, BerneyDMet al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study. Lancet Oncol 2011; 12: 245-255.